PATIENT INFORMATION LEAFLET
|
|
|
- Brittney Holland
- 5 years ago
- Views:
Transcription
1 HAMAZINC 5.35% + 18% cream For external use only. PATIENT INFORMATION LEAFLET Active substances: Each gram of cream contains; 53.5 mg hamamelis virginiana distillate and mg zinc oxide. Excipients: Methyl paraben (E218), ethyl paraben (E214), propyl paraben (E216), cetomagrogol 1000, propylene glycol, cetostearyl alcohol, liquid paraffin, white paraffin and deionized water. Read this PATIENT INFORMATION LEAFLET carefully before you start taking this medicine, because it contains important information for you. This medicine is available without prescription for you to treat minor disorders without a doctor s help, with the recommendation of your pharmacist. However, you still need to use HAMAZINC carefully to get the best results from it. Keep this leaflet. You may need to read it again. If you have any further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you only, do not pass it on to others. When you go to a doctor or hospital while using this medicine, tell your doctor that you are receiving this medicine. Follow strictly what has written on this leaflet. Do not use higher or lower doses than the dose which was recommended for you. What is in this leaflet: 1. What HAMAZINC is and what is it used for? 2. Before you use HAMAZINC 3. How to use HAMAZINC? 4. Possible side effects 5. How to store HAMAZINC? 1. What HAMAZINC is and what is it used for? HAMAZINC is a white appearance cream used externally containing hamamelis virginiana distillate and zinc oxide which is marketed in 30 g, 60 g and 90 g aluminum tubes. The Hamamelis virginiana aqueous extract present in HAMAZINC composition has tissue constrictor (astringent), local stops bleeding (hemostatic) and reduces inflammation (anti-inflammatory) activities. Following skin injuries, the tissue constrictor effect provides tissue thickening by causing coagulation of skin proteins at the injury site. Sayfa 1 / 5
2 The local hemostatic effect reduces bleeding time and accelerates clotting at the injury site following a skin injury. It relieves signs and symptoms of inflammation of the skin with its anti-inflammatory activity. Zinc oxide reduces inflammation and tissue death in damaged and injured skin and accelerates wound healing in the injury site by increasing skin cell growth. HAMAZINC; - Diaper rash in babies and young children - Maintenance treatment for diaper rash aggravating due to fungal infections or bacterial infections - First and second degree burns/sunburn - Superficial skin lesions (injuries) including scratches and cuts - Care and prevention of cracked nipples in nursing mothers - Care and protection of dry, cracked, split skin (including skin of the elderly and treatment of diabetic foot) - This product can be used as an adjunct to treatment of skin disease which is manifested with tissue disorders such as redness, itching, exudate, scabbing caused by various reasons as a result of treatment with other medicines, rapidly growing and exudating wound like skin damage due to rubbing or microbes such as fungus on skin and especially leg wounds and wounds that occurs in patients lying down for a long time. 2. Before you use HAMAZINC DO NOT use HAMAZINC Do not use if you are allergic to any of the ingredients of HAMAZINC. TAKE SPECIAL CARE with HAMAZINC in the following conditions: Contact of HAMAZINC with eyes should be avoided. In case of contact with eyes, eyes should be washed with plenty of water. If current complaints persist or worsen despite using HAMAZINC, a doctor should be consulted. Please consult your doctor, even if these statements were applicable to you at any time in the past. Using HAMAZINC with food and drink: There is no special indication regarding using HAMAZINC with food and drink. Pregnancy Ask your doctor or pharmacist for advice before taking the medicine. For Hamamelis virginiana, no clinical data on exposed pregnancies are available. For zinc oxide, no clinical data on exposed pregnancies are available. Animal studies are also unavailable. Sayfa 2 / 5
3 Caution should be used if HAMAZINC is to be used during pregnancy. If you notice that you are pregnant during treatment, please consult your doctor immediately. Breast-feeding Ask your doctor or pharmacist for advice before taking the medicine. It is not known whether Hamamelis virginiana passes into human milk. Excretion of Hamamelis virginiana into milk in animals was also not investigated. It is not known whether zinc oxide passes into human milk. Consult your doctor about using HAMAZINC during lactation. Driving and using machines: There is no known effect on driving and using machines. Important information about some of the excipients of HAMAZINC Local skin reactions (for example, contact dermatitis with irritant or allergic ingredients directly associated with skin inflammation) and skin irritation may rarely occur due to propylene glycol and cetostearyl alcohol contents. The methylparaben (E218), ethylparaben (E214), propylparaben (E216) contents of HAMAZINC may cause allergic (potentially delayed) reactions. Using with other medicines No interaction of HAMAZINC with other medicinal products via the topical route was reported. Please tell your doctor or pharmacist if you are taking or have recently taken any other prescription or nonprescription medicine. 3. How to use HAMAZINC? Instructions for appropriate method and dose/frequency of administration: Apply HAMAZINC few times a day to the lesion area. There is no time limitation to using HAMAZINC. Route and method of administration: Apply HAMAZINC to the lesion area as a thin layer. Lesion area can be covered with gauze bandage following application, if necessary. For nipple care of nursing mothers, HAMAZINC is applied to the nipples after each breastfeeding. Various age groups: Use in children: Use in elderly: Special Populations Kidney/Liver failure: If you have the impression that the effect of HAMAZINC is too strong or too weak, talk to your doctor or pharmacist. Sayfa 3 / 5
4 If you have used more HAMAZINC than you should: If you may have taken more HAMAZINC than you should, talk to a doctor or pharmacist. If you forget to use HAMAZINC: Do not use double dose to make up for the dose you forgot. If you stop using HAMAZINC: No effect is expected. 4. Possible side effects Like all medicines, side effects can occur in people sensitive to the contents of HAMAZINC. If any of the following occur stop using HAMAZINC and IMMEDIATELY inform your doctor or go to the nearest emergency department. Swelling of hands, feet, ankles, face, lips or specific swelling of mouth cavity and throat causing difficulty in breathing These are very serious side effects. If you have any of them, this means you have serious allergy for HAMAZINC. You may need emergency medical care or hospitalization. All of these very serious side effects occur very rarely. Side effects are classified by the following categories: Very common (occurring in at least 1 of 10 patients); Common (occurring in less than 1 of 10 but in more than 1 of 100 patients); Uncommon (occurring in less than 1 of 100 but more than 1 in patients); Rare (occurring in less than 1 in patients); Very rare (occurring in less than 1 of patients); Unknown (Cannot be estimated from the available data), Uncommon (occurring in less than 1 of 100 but more than 1 in patients) Skin rashes that spread uniformly in the skin, suddenly spontaneously, and disappear without recurring skin changes, symptomatic skin rash (exanthema) Skin irritation, itching, burning and stinging sensation Skin redness (erythema) Dry skin Unknown (cannot be estimated with the available data) Allergic reaction Skin irritation (eczema), which is caused by irritant or allergenic substances, direct skin contact inflammation (contact dermatitis), tissue disorders such as redness, itching, watering, incrustation Hives (urticarial), allergic skin rash Allergic skin disorder (angioneurotic edema) caused by large, painless swelling that is restricted to a certain area under the skin If you notice any side effects not mentioned in this leaflet inform your doctor or pharmacist. Sayfa 4 / 5
5 5. How to store HAMAZINC Keep in the original package and out of the reach and sight of children. Store at room temperature below 25 Use in accordance with the expiry date. Use HAMAZINC before the expiry date indicated on the tube or package. Do not use HAMAZINC if you notice any damage to the product and/or package. Marketing authorization holder: Berko İlaç ve Kimya Sanayi A.Ş. Yenişehir Mah. Özgür Sok. No: Ataşehir/İstanbul-Turkey (Pbx) (Fax) Manufacturer: Berko İlaç ve Kimya Sanayi A.Ş. Adil Mah. Yörükler Sok. No: 2 Sultanbeyli/İstanbul-Turkey (Pbx) (Fax) This patient information leaflet was last approved on 28/05/2018. Sayfa 5 / 5
PATIENT INFORMATION LEAFLET
HAMAZINC cream For topical use. PATIENT INFORMATION LEAFLET Active substance(s): Each 1 gram cream contains 53.5 mg hamamelis virginiana distillate and 180.00 mg zinc oxide. Excipient(s): Methylparaben(E218),
PATIENT INFORMATION LEAFLET
FERIFER-40 Oral Solution, 40 mg/5 ml For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each one spoon solution (5 ml) contains 40 mg of iron (as iron III polymaltose complex). Excipient(s):
PATIENT INFORMATION LEAFLET
KLOBATE 0.05% cream For topical use. PATIENT INFORMATION LEAFLET Active substance(s): 0.05% clobetasol contains 17-propionate. Excipient(s): Stearyl alcohol, propylene glycol, vaseline, sorbitan sesquioleate,
PATIENT INFORMATION LEAFLET
DROPOLEV 60 mg/ml oral drops, 30 ml For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each 1 ml solution contains 60 mg levodropropizine. Excipient(s): Methyl paraben sodium, propylene glycol,
PATIENT INFORMATION LEAFLET. Active substances: Each 5 ml syrup (1 spoon) contains 2.5 mg desloratadine.
ALORES 2.5mg/5ml syrup For oral use only. PATIENT INFORMATION LEAFLET Active substances: Each 5 ml syrup (1 spoon) contains 2.5 mg desloratadine. Excipients: Propylene glycol, sorbitol 70% (E420), citric
PATIENT INFORMATION LEAFLET
ZINCO-K 15 mg/5 ml syrup For oral use PATIENT INFORMATION LEAFLET Active substance(s): Each 5 ml syrup (1 spoon) contains 15 mg of zinc as zinc sulphate heptahydrate. Excipient(s): Sorbitol (%70), maltitol,
PATIENT INFORMATION LEAFLET
ALORES 2.5mg/5ml Syrup For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each 5 ml syrup (1 spoon) contains desloratadine 2.5 mg. Excipient(s): Propylene glycol, sorbitol 70%, citric acid
PATIENT INFORMATION LEAFLET
FERROZINC-G syrup, 100 ml For oral use PATIENT INFORMATION LEAFLET Active substance(s): Each 5 ml (1 spoon) syrup contains 40 mg iron (as ferrous gluconate) and 15 mg zinc (as zinc gluconate). Excipient(s):
PATIENT INFORMATION LEAFLET
N-CORT 0.055% Nasal Spray For nasal use. PATIENT INFORMATION LEAFLET Active substance(s): Triamcinolone acetonide (w/w%) 0.055 Excipient(s): Benzalkonium chloride 50%, sodium hydroxide, hydrochloric acid,
PATIENT INFORMATION LEAFLET
MAGNEZINC Film Coated Tablets For oral use. PATIENT INFORMATION LEAFLET Active substance(s): Each film tablet contains 30 mg zinc equivalent to 82.6 mg zinc sulfate monohydrate and 300 mg magnesium equivalent
PATIENT INFORMATION LEAFLET
N-CORT 0.055% nasal spray, suspension It is used by spraying into the nose. Active substance: (w/w%) Triamcinolone acetonide 0.055 PATIENT INFORMATION LEAFLET Excipients: Benzalkonium chloride 50%, sodium
PACKAGE LEAFLET: INFORMATION FOR THE USER Clotrimazole Cream 1%
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Clotrimazole Cream 1% Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
PATIENT INFORMATION LEAFLET
ENFLUAT 0.4 % Sterile Eye Drops Applied dropwise to the eye. PATIENT INFORMATION LEAFLET Drug substance: Each 1ml contains 4 mg ketorolac tromethamine. Excipient(s): Benzalconium chloride, sodium chloride,
Patient Leaflet : Information for the user Locoid Cream 0.1% w/w Hydrocortisone butyrate
Patient Leaflet : Information for the user Locoid Cream 0.1% w/w Hydrocortisone butyrate Read all of this leaflet carefully before you start using this medicine because it contains important information
1g cream or ointment contains 1 mg methylprednisolone aceponate.
CONSUMER MEDICINE INFORMATION ADVANTAN 1g cream or ointment contains 1 mg methylprednisolone aceponate. What is in this leaflet Please read this leaflet carefully before you start using ADVANTAN. It will
PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET BEVIT-B12 film tablet For oral use. Active substance: Each film-coated tablet contains 250 mg pyridoxine hydrochloride (Vitamin B 6 ), 250 mg thiamine hydrochloride (Vitamin
Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam
Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam Read all of this leaflet carefully before you start using this medicine because it contains important information
PATIENT INFORMATION LEAFLET
DESIFEROL 2000 IU Film Coated Tablets For oral use only PATIENT INFORMATION LEAFLET Active substance(s): Each film coated tablet contains 2000 I.U. (50 ) vitamin D3 (derived from sheep wool). Excipient(s):
Patient Information Leaflet
Patient Information Leaflet Ibuprofen 5% w/w Gel Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have any further questions
PATIENT INFORMATION LEAFLET TREGS
PATIENT INFORMATION LEAFLET TREGS 1 g IM powder for injection For intramuscular use. Active ingredient: Each vial contains: 1000 mg ceftriaxone as 1192.89 mg ceftriaxone sodium. Each ampoule contains:
Package leaflet: Information for the user. Fluticrem 0.05% cream Fluticasone propionate
Package leaflet: Information for the user Fluticrem 0.05% cream Fluticasone propionate Read all of this leaflet carefully before you start using this medicine because it contains important information
Package leaflet: Information for the user. Zidoval 7.5 mg/g Vaginal Gel Metronidazole
Package leaflet: Information for the user Zidoval 7.5 mg/g Vaginal Gel Metronidazole Read all of this leaflet carefully before you start using this medicine because it contains important information for
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end
CONSUMER MEDICINE INFORMATION CLOTRIZONE CREAM
CONSUMER MEDICINE INFORMATION CLOTRIZONE CREAM Clotrimazole 1% w/w and hydrocortisone acetate 1% w/w What is in this leaflet This leaflet answers some common questions about It does not contain all the
Package leaflet: Information for the patient. Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone)
PACKAGE LEAFLET Package leaflet: Information for the patient Xemacort 20 mg/g + 1 mg/g cream (fusidic acid and betamethasone) Read all of this leaflet carefully before you start using this medicine because
PACKAGE LEAFLET: INFORMATION FOR THE USER. Lidokain Isdin 40 mg/g cream. Lidocaine
PACKAGE LEAFLET: INFORMATION FOR THE USER Lidokain Isdin 40 mg/g cream Lidocaine Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
PATIENT INFORMATION LEAFLET
PATIENT INFORMATION LEAFLET FERROZINC Capsules For oral use. Active substance(s): Each 1 capsule contains; 261.29 mg ferrous fumarate equivalent to 79.87 mg iron, 68.7 mg zinc sulfate monohydrate equivalent
TAFEN NASAL 50mcg nasal spray, suspension
PACKAGE LEAFLET: INFORMATION FOR THE USER TAFEN NASAL 50mcg nasal spray, suspension BUDESONIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER
Fusidic acid 20 mg/g cream Page 1 of 6 1.3.1 PACKAGE LEAFLET: INFORMATION FOR THE USER AffusineAffusine 20 mg/g cream Fusidic Acid Read all of this leaflet carefully before you start using this medicine
Package leaflet: Information for the patient
Package leaflet: Information for the patient Anugesic HC Cream pramocaine hydrochloride, hydrocortisone acetate, zinc oxide, balsam peru, benzyl benzoate, bismuth oxide Read all of this leaflet carefully
Hydrocortisyl Skin Cream 1% Hydrocortisone
PACKAGE LEAFLET: INFORMATION FOR THE USER Hydrocortisyl Skin Cream 1% Hydrocortisone Is this leaflet hard to see or read? Phone 01403 5600 for help Read all of this leaflet carefully before you start using
PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
FASTUM 2.5% gel PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT FASTUM GEL IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER FASTUM 2.5% gel KETOPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines the
PATIENT INFORMATION LEAFLET TEXAMER
SCHEDULING STATUS: S2 PROPRIETARY NAME AND DOSAGE FORM: film-coated tablets Read all of this leaflet carefully because it contains important information for you. is available without a doctor s prescription,
PACKAGE LEAFLET: INFORMATION FOR THE USER. GRAZAX 75,000 SQ-T oral lyophilisate
PACKAGE LEAFLET: INFORMATION FOR THE USER GRAZAX 75,000 SQ-T oral lyophilisate Standardised allergen extract of grass pollen from Timothy (Phleum pratense) Read all of this leaflet carefully before you
PATIENT INFORMATION LEAFLET
FERROZINC-G 40 mg/15 mg syrup For oral use PATIENT INFORMATION LEAFLET Active substance(s): Each 5 ml (1 spoon) syrup contains 344 mg iron II gluconate equivalent to 40 mg and 105 mg zinc gluconate equivalent
Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime
Package leaflet: Information for the user Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime Read all of this leaflet carefully before you start taking this medicine because it contains important
Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride
Package leaflet: Information for the patient / / 30 mg/5 ml syrup Ambroxol hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information
Package leaflet: Information for the patient. Mometasone furoate 0.1%w/w Ointment (mometasone furoate)
Package leaflet: Information for the patient Mometasone furoate 0.1%w/w Ointment (mometasone furoate) Read all of this leaflet carefully before you start using this medicine because it contains important
Core Safety Profile. Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% SK/H/PSUR/0005/001 Date of FAR:
Core Safety Profile Active substance: Terbinafine Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% P-RMS: SK/H/PSUR/0005/001 Date of FAR: 08.06.2012 4.3 Contraindications Hypersensitivity
Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate
Package leaflet: Information for the user PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate Read all of this leaflet carefully before you start using this medicine
2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient
Package Leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start taking this medicine
Consumer Medicine Information PIMAFUCORT
Consumer Medicine Information PIMAFUCORT 1% Hydrocortisone, 1% Natamycin and 0.35% Neomycin Cream and Ointment What is in this leaflet This leaflet answers some common questions about Pimafucort Cream
PATIENT INFORMATION LEAFLET. Excipients: Sorbitol 70% (E420), glycerol, hydroxyethyl cellulose, mint flavor, purified water.
HEKSOBEN gargle For oral rinse PATIENT INFORMATION LEAFLET Active substance: 100 ml solution contains 120 mg (0.12%) chlorhexidine digluconate and 150 mg (0.15%) benzydamine hydrochloride. Excipients:
PACKAGE LEAFLET: INFORMATION FOR THE USER. Cinfalair 4 mg chewable tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Cinfalair 4 mg chewable tablets Read all of this leaflet carefully before your child starts taking this medicine. Keep this leaflet. You may need to read it again.
Package leaflet: Information for the user. Zoviduo 50 mg/g and 10 mg/g cream. Aciclovir and Hydrocortisone
The PL includes alternative texts for different legal status in different countries as follows: -Boxed texts are only applicable for OTC versions. -[Grey-shaded texts in brackets] are only applicable for
PATIENT INFORMATION LEAFLET. Urea 10% w/w Cream
PATIENT INFORMATION LEAFLET Urea 10% w/w Cream Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However, you still
Package leaflet: Information for the user. Ebateva 20 mg Orodispersible Tablets. Ebastine
Package leaflet: Information for the user Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets Ebastine Read all of this leaflet carefully before you start taking this medicine because
PACKAGE LEAFLET: INFORMATION FOR THE USER. ZADITEN 1 mg/5 ml Oral Solution. Ketotifen (as Ketotifen hydrogen fumarate)
PACKAGE LEAFLET: INFORMATION FOR THE USER ZADITEN 1 mg/5 ml Oral Solution Ketotifen (as Ketotifen hydrogen fumarate) Read all of this leaflet carefully because it contains important information for you.
1. WHAT IS CANESTEN HC CREAM AND WHAT IS IT USED FOR?
Canesten HC Cream Clotrimazole 1.0% w/w Hydrocortisone 1.0% w/w Read all of this leaflet carefully because it contains important information for you. Keep this leaflet. You may need to read it again. If
Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride
Package leaflet: Information for the user Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride Read all of this leaflet carefully before you start using this medicine because
Consumer Medicine Information TOPICIL. Please read this leaflet carefully before you start using Topicil Capsules.
Clindamycin hydrochloride Capsules 150 mg What is in this leaflet Consumer Medicine Information TOPICIL Please read this leaflet carefully before you start using Topicil Capsules. This leaflet answers
Package leaflet: Information for the patient. Calcium Folinate 15 mg Tablets calcium folinate
PACKAGE LEAFLET Package leaflet: Information for the patient Calcium Folinate 15 mg Tablets calcium folinate Read all of this leaflet carefully before you start taking this medicine because it contains
LYSOBACT COMPLETE SPRAY ( ) mg / ml Oromucosal spray, solution
PACKAGE LEAFLET: INFORMATION FOR THE USER LYSOBACT COMPLETE SPRAY (20 + 1.5 + 0.5) mg / ml Oromucosal spray, solution LYSOZYME, CETYLPYRIDINIUM, LIDOCAINE This leaflet is a copy of the Summary of Product
PATIENT INFORMATION LEAFLET. Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate
PATIENT INFORMATION LEAFLET Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate Read all of this leaflet carefully before you start using this medicine Keep this leaflet. You may need
Package leaflet: Information for the user
Package leaflet: Information for the user Betnovate Cream betamethasone valerate Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
PATIENT INFORMATION LEAFLET POLLENTYME S AND TABS
SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS (tablets) POLLENTYME S (syrup) Read all of this leaflet carefully because it contains important information
RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
Package leaflet: Information for users. Imodium 2 mg orodispersible tablets Loperamide hydrochloride
MARKETING AUTHORISATION NO. 7810/2015/01-02-03-04 Annex 1 Package leaflet Package leaflet: Information for users Imodium 2 mg orodispersible tablets Loperamide hydrochloride Read all of this leaflet carefully
1. What Solpadol is and what it is used for
PATIENT INFORMATION LEAFLET SOLPADOL 30mg/500mg CAPLETS Codeine Phosphate and Paracetamol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
PACKAGE LEAFLET: INFORMATION FOR THE USER. Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate
PACKAGE LEAFLET: INFORMATION FOR THE USER Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate Read all of this leaflet carefully before you start using this medicine. Keep
PATIENT INFORMATION LEAFLET EFFERFLU C IMMUNE BOOSTER. EFFERFLU C IMMUNE BOOSTER has not been evaluated by the Medicines Control
is an immune booster. has not been evaluated by the Medicines Control Council. is not intended to diagnose, treat, cure or prevent any disease. SCHEDULING STATUS: Not applicable PROPRIETARY NAME, STRENGTH
Package leaflet: Information for the patient. Migräne-Kranit 500 mg Tablets. Active substance: phenazone
Package leaflet: Information for the patient Migräne-Kranit 500 mg Tablets Active substance: phenazone Read all of this leaflet carefully before you start taking this medicine because it contains important
PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES. Lubiprostone
PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES Lubiprostone This medicine is subject to additional monitoring. This will allow quick identification of new
RESOLVE PLUS 1.0 Hydrocortisone, miconazole nitrate
RESOLVE PLUS 1.0 Hydrocortisone, miconazole nitrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Resolve Plus 1.0. It does not contain all the
PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for
PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If
If you have any questions about how Letrozole Tablets works or why this medicine has been prescribed for you, ask your doctor.
PACKAGE LEAFLET: Information for the user Letrozole 2.5 mg Film-coated Tablets Letrozole Read all of this leaflet carefully before you start taking this medicine because it contains important information
PHOLCODINE. Please follow the instructions on the packaging of the medicine you purchased and in this leaflet before you start using pholcodine.
PHOLCODINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains pholcodine. This leaflet is intended to provide information on the active ingredient
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate)
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate) Pfizer Logo Read all of this leaflet carefully before you start taking this
Proctosedyl Ointment Hydrocortisone/Cinchocaine hydrochloride/framycetin sulphate/aesculin
Proctosedyl Ointment Hydrocortisone/Cinchocaine hydrochloride/framycetin sulphate/aesculin Is this leaflet hard to see or read? Phone 01 403 5600 for help Read all of this leaflet carefully before you
Dorzolamide 20 mg/ml Eye Drops, Solution
PACKAGE LEAFLET: INFORMATION FOR THE USER Dorzolamide 20 mg/ml Eye Drops, Solution (Dorzolamide hydrochloride) Read all of this leaflet carefully before you start using this medicine because it contains
Package leaflet: Information for the patient. Bromhexin Krewel Meuselbach Drops 12 mg/ml. Bromhexine hydrochloride
Package leaflet: Information for the patient Bromhexin Krewel Meuselbach Drops 12 mg/ml Bromhexine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains
ILUVIEN 190 micrograms intravitreal implant in applicator (fluocinolone acetonide)
ILUVIEN 190 micrograms intravitreal implant in applicator (fluocinolone acetonide) Read all of this information carefully before you are given this medicine because it contains important information for
Package leaflet: Information for the user. Qutenza 179 mg cutaneous patch capsaicin
Package leaflet: Information for the user Qutenza 179 mg cutaneous patch capsaicin Read all of this leaflet carefully before you start using this medicine because it contains important information for
Zatamil Mometasone furoate 0.1% w/w
Zatamil Mometasone furoate 0.1% w/w CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Zatamil. It does not contain all the available information. It
Do not use Allergo-COMOD eye drops - if you are hypersensitive against sodium cromoglicate (Ph. Eur.) or one of the other ingredients.
Allergo-COMOD eye drops 20 mg/ml eye drops Active substance: Sodium cromoglicate (Ph. Eur.) Read all of this leaflet carefully because it contains important information for you. This medicine is available
Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)
Package leaflet: Information for the patient Loratadine 10 mg Tablets (loratadine) Read all of this leaflet carefully before you start taking this medicine because it contains important information for
Unofficial translation of the German package leaflet. Package leaflet: Information for the user
Unofficial translation of the German package leaflet Package leaflet: Information for the user Soventol HydroCort 0.5% Spray 5 mg/g solution Active substance: Hydrocortisone For use in adults and children
Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000
Package leaflet: Information for the user 10 g powder for oral solution in sachet Macrogol 4000
Package leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine
Package leaflet: Information for the patient Histaclar 10 mg Film-coated Tablets loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information
Cutivate 0.05% w/w Cream fluticasone propionate
Package Leaflet: Information for the User Cutivate 0.05% w/w Cream fluticasone propionate Read all of this leaflet carefully before you start using this medicine because it contains important information
Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets
Package leaflet: Information for the patient Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets Acetylsalicylic acid Read all of this leaflet carefully before you
Read this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. If you have further questions, please ask your doctor or your pharmacist.
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: DYNA BEZAFIBRATE 400 SR (slow release tablets) Read this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. Keep
POLLENTYME S and Tabs Pharma Dynamics (Pty) Ltd Version: July 2017 (G1639) Word copy of G1639 PATIENT INFORMATION LEAFLET FOR POLLENTYME S AND TABS
PROPOSED FINAL PATIENT INFORMATION LEAFLET FOR POLLENTYME TABLETS & POLLENTYME S PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S1 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: POLLENTYME TABLETS
Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin
Package leaflet: Information for the patient NEGABAN 1g, powder for solution for injection or infusion Temocillin Read all of this leaflet carefully before you start using this medicine because it contains
PACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER DYSPORT 500 units Powder for solution for injection Clostridium botulinum type A toxin-haemagglutinin complex Read all of this leaflet carefully, before you start
Dalacin C 150 mg Hard Capsules Clindamycin (as clindamycin hydrochloride)
Package leaflet: Information for the patient Dalacin C 150 mg Hard Capsules Clindamycin (as clindamycin hydrochloride) Read all of this leaflet carefully before you start taking this medicine because it
Zinnat can also be used: to treat Lyme disease (an infection spread by parasites called ticks).
[GlaxoSmithKline Logo] Package Leaflet: Information for the Patient Zinnat Tablets 125 mg and 250 mg cefuroxime Read all of this leaflet carefully before you start taking this medicine because it contains
ANBESOL Liquid Lidocaine Hydrochloride, Chlorocresol and Cetylpyridinium Chloride
ANBESOL Liquid Lidocaine Hydrochloride, Chlorocresol and Cetylpyridinium Chloride PATIENT INFORMATION LEAFLET Read all of this leaflet carefully before using this medicine as it contains important information
PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone
PACKAGE LEAFLET: INFORMATION FOR THE USER ToboDexin 3 mg/g+1 mg/g eye ointment Tobramycin + Dexamethasone Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You
PACKAGE LEAFLET: INFORMATION FOR THE USER. Flutarzole 0,05% w/w cream, Fluticasone propionate
PACKAGE LEAFLET: INFORMATION FOR THE USER Flutarzole 0,05% w/w cream, Fluticasone propionate 1. IDENTIFICATION OF THE MEDICINAL PRODUCT 1.1. Trade name Flutarzole 1.2. Composition Active substance: Fluticasone
TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine.
TRIPROLIDINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains triprolidine. This leaflet is intended to provide information on the active ingredient
PATIENT INFORMATION LEAFLET AMLOC RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it
Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine
Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Always
PACKAGE LEAFLET: INFORMATION FOR THE USER. Rectogesic 4 mg/g Rectal Ointment Glyceryl trinitrate
PACKAGE LEAFLET: INFORMATION FOR THE USER Rectogesic 4 mg/g Rectal Ointment Glyceryl trinitrate Read all of this leaflet carefully before you start using this medicine because it contains important information
PACKAGE LEAFLET: INFORMATION FOR THE USER Paracodin 0.20% w/w Syrup (dihydrocodeine hydrogen tartrate)
PACKAGE LEAFLET: INFORMATION FOR THE USER Paracodin 0.20% w/w Syrup (dihydrocodeine hydrogen tartrate) Read all of this leaflet carefully before you start taking this medicine because it contains important
Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin
Package leaflet: Information for the patient Trasylol 10,000 KIU/ml solution for injection or infusion Aprotinin Read all of this leaflet carefully before you are given this medicine because it contains